Literature DB >> 6435409

Regulation of low density lipoprotein uptake and degradation in different animals species.

J M Dietschy, D K Spady.   

Abstract

These various observations suggest that the intestinal-hepatic axis plays a key role in the regulation of cholesterol balance in the whole animal and the circulating levels of LDL-cholesterol. Nearly all sterol which enters or leaves the body must do so through the intestine and liver. Changes in the rate of entry or exit of cholesterol (or bile acids) from the animal are met by appropriate reciprocal changes in the rates of cholesterol synthesis in these two organs. As long as these adaptive changes in synthesis are adequate to meet the changing needs for cholesterol in the animal, the rates of receptor-mediated LDL degradation by the liver and intestine remain essentially unchanged as does the plasma LDL-cholesterol concentration. Only when the changes in cholesterol synthesis are inadequate to meet the changing sterol needs (or are blocked by drug administration (22] does the liver increase its rate of receptor-mediated LDL uptake which, in turn, results in significant alterations in circulating plasma LDL-cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6435409     DOI: 10.1007/978-3-0348-7235-5_21

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  3 in total

Review 1.  Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.

Authors:  Helen H Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  In vivo D2O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS.

Authors:  Jose Castro-Perez; Stephen F Previs; David G McLaren; Vinit Shah; Kithsiri Herath; Gowri Bhat; Douglas G Johns; Sheng-Ping Wang; Lyndon Mitnaul; Kristian Jensen; Robert Vreeken; Thomas Hankemeier; Thomas P Roddy; Brian K Hubbard
Journal:  J Lipid Res       Date:  2010-09-30       Impact factor: 5.922

3.  The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

Authors:  Melroy X Miranda; Lambertus J van Tits; Christine Lohmann; Tasneem Arsiwala; Stephan Winnik; Anne Tailleux; Sokrates Stein; Ana P Gomes; Vipin Suri; James L Ellis; Thomas A Lutz; Michael O Hottiger; David A Sinclair; Johan Auwerx; Kristina Schoonjans; Bart Staels; Thomas F Lüscher; Christian M Matter
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.